[go: up one dir, main page]

CL2021002847A1 - Combination therapies comprising apremilast and tyk2 inhibitors - Google Patents

Combination therapies comprising apremilast and tyk2 inhibitors

Info

Publication number
CL2021002847A1
CL2021002847A1 CL2021002847A CL2021002847A CL2021002847A1 CL 2021002847 A1 CL2021002847 A1 CL 2021002847A1 CL 2021002847 A CL2021002847 A CL 2021002847A CL 2021002847 A CL2021002847 A CL 2021002847A CL 2021002847 A1 CL2021002847 A1 CL 2021002847A1
Authority
CL
Chile
Prior art keywords
apremilast
combination therapies
tyk2 inhibitors
tyk2
inhibitors
Prior art date
Application number
CL2021002847A
Other languages
Spanish (es)
Inventor
Peter Henry Schafer
Robert Plenge
Mary Adams
Lisa Beebe
Gilles Buchwalter
Tiffany Carr
Te-Chen Tzeng
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CL2021002847A1 publication Critical patent/CL2021002847A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Se proporcionan en la presente métodos para tratar enfermedades y trastornos que responden a la inhibición de PDE4 que comprende administrar apremilast y un inhibidor de Tyk2 a un sujeto. También se proporcionan en la presente composiciones farmacéuticas que comprenden apremilast y un inhibidor de Tyk2.Provided herein are methods of treating diseases and disorders responsive to PDE4 inhibition comprising administering apremilast and a Tyk2 inhibitor to a subject. Also provided herein are pharmaceutical compositions comprising apremilast and a Tyk2 inhibitor.

CL2021002847A 2019-04-30 2021-10-29 Combination therapies comprising apremilast and tyk2 inhibitors CL2021002847A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/029772 WO2020222773A1 (en) 2019-04-30 2019-04-30 Combination therapies comprising apremilast and tyk2 inhibitors

Publications (1)

Publication Number Publication Date
CL2021002847A1 true CL2021002847A1 (en) 2022-07-22

Family

ID=66476870

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2021002847A CL2021002847A1 (en) 2019-04-30 2021-10-29 Combination therapies comprising apremilast and tyk2 inhibitors

Country Status (14)

Country Link
EP (2) EP3962475A1 (en)
JP (2) JP2022537877A (en)
KR (2) KR20220002488A (en)
CN (3) CN114269336A (en)
AU (2) AU2019443366A1 (en)
BR (2) BR112021021809A2 (en)
CA (2) CA3138473A1 (en)
CL (1) CL2021002847A1 (en)
CO (2) CO2021015622A2 (en)
IL (2) IL287665A (en)
MA (1) MA55799A (en)
MX (2) MX2021013317A (en)
SG (2) SG11202112043PA (en)
WO (2) WO2020222773A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020222773A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors
MX2023009685A (en) 2021-02-19 2023-10-30 Sudo Biosciences Ltd Tyk2 inhibitors and uses thereof.
EP4294808A1 (en) 2021-02-19 2023-12-27 Sudo Biosciences Limited Tyk2 inhibitors and uses thereof
WO2023049241A1 (en) * 2021-09-23 2023-03-30 Bristol-Myers Squibb Company Methods of treating hair-loss disorders with tyk2 inhibitors
CN119013277A (en) 2021-10-25 2024-11-22 凯麦拉医疗公司 TYK2 degrading agent and application thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
GB0709031D0 (en) 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
TW201040162A (en) * 2009-05-06 2010-11-16 Portola Pharm Inc Inhibitors of JAK
CN103298794A (en) 2010-11-09 2013-09-11 塞尔卓姆有限公司 Pyridine compounds and aza analogues thereof as TYK2 inhibitors
AU2012249536B2 (en) * 2011-04-28 2016-09-22 Amgen (Europe) GmbH Methods and compositions using PDE4 inhibitors for the treatment and management of autoimmune and inflammatory diseases
MX373934B (en) * 2011-12-27 2025-03-05 Celgene Corp Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione
MX352928B (en) 2012-01-10 2017-12-13 Hoffmann La Roche Pyridazine amide compounds and their use as syk inhibitors.
EP2832734A4 (en) 2012-03-28 2015-08-26 Takeda Pharmaceutical Heterocyclic compound
EP2855451B1 (en) 2012-05-24 2017-10-04 Cellzome Limited Heterocyclyl pyrimidine analogues as tyk2 inhibitors
JP6266639B2 (en) 2012-11-08 2018-01-24 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Alkylamide-substituted pyrimidine compounds useful for the modulation of IL-12, IL-23 and / or IFNα
EA028814B1 (en) * 2012-11-08 2018-01-31 Бристол-Майерс Сквибб Компани AMIDE-SUBSTITUTED HETEROCYCLIC COMPOUNDS USEFUL AS MODULATORS OF IL-12, IL-23 AND/OR IFNα RESPONSES
WO2014151180A1 (en) * 2013-03-14 2014-09-25 Celgene Corporation Treatment of psoriatic arthritis using apremilast
EP3029031A4 (en) 2013-07-30 2017-01-11 Takeda Pharmaceutical Company Limited Heterocyclic compound
AU2013399913B2 (en) 2013-09-03 2018-03-15 Sareum Limited Pharmaceutical compounds
TWI582077B (en) 2013-11-07 2017-05-11 必治妥美雅史谷比公司 Alkyl-amide-substituted pyridyl compounds useful as modulators of il-12, il-23 and/or ifnα responses
WO2015089143A1 (en) 2013-12-10 2015-06-18 Bristol-Myers Squibb Company Imidazopyridazine compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
WO2015091584A1 (en) 2013-12-18 2015-06-25 F. Hoffmann-La Roche Ag Thiazolopyridine compounds, compositions and their use as tyk2 kinase inhibitors
US9834548B2 (en) * 2014-02-14 2017-12-05 Portola Pharmaceuticals, Inc. Pyridazine compounds as JAK inhibitors
AU2015222865B2 (en) 2014-02-28 2019-06-20 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
US10300042B2 (en) * 2014-06-23 2019-05-28 Celgene Corporation Apremilast for the treatment of a liver disease or a liver function abnormality
EP3188745A1 (en) * 2014-08-15 2017-07-12 Celgene Corporation Dosage titration of apremilast for the treatment of diseases ameliorated by pde4 inhibition
NO2721710T3 (en) 2014-08-21 2018-03-31
WO2016047678A1 (en) 2014-09-25 2016-03-31 武田薬品工業株式会社 Heterocyclic compound
TWI788655B (en) 2015-02-27 2023-01-01 美商林伯士拉克許米公司 Tyk2 inhibitors and uses thereof
JP6802263B2 (en) 2015-09-02 2020-12-16 ニンバス ラクシュミ， インコーポレイテッド TYK2 inhibitor and its use
WO2017144995A1 (en) 2016-02-24 2017-08-31 Pfizer Inc. Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors
CN110036015B (en) 2016-10-07 2022-07-19 百时美施贵宝公司 Imidazopyridazine compounds useful as modulators of IL-12, IL-23 and/or IFN alpha response
CN115448916A (en) 2016-10-14 2022-12-09 林伯士拉克许米公司 TYK2 inhibitors and uses thereof
IL266109B1 (en) 2016-10-21 2025-01-01 Nimbus Lakshmi Inc Tyk2 inhibitors and uses thereof
EP3532473B1 (en) 2016-10-28 2021-09-29 Bristol-Myers Squibb Company Heterobicyclic compounds useful as modulators of il-12, il-23 and/or ifn alpha responses
JP7012082B2 (en) 2016-11-17 2022-01-27 ブリストル－マイヤーズ スクイブ カンパニー Imidazopyridazine regulator of IL-12, IL-23 and / or IFN-alpha
GB2562702B (en) 2017-03-06 2022-05-18 Linear Shaped Ltd Frame and linear shaped charge
US10336752B2 (en) * 2017-03-08 2019-07-02 Nimbus Lakshmi, Inc. TYK2 inhibitors, uses, and methods for production thereof
WO2020222773A1 (en) * 2019-04-30 2020-11-05 Celgene Corporation Combination therapies comprising apremilast and tyk2 inhibitors

Also Published As

Publication number Publication date
IL287665A (en) 2022-07-01
KR20220002488A (en) 2022-01-06
CA3138686A1 (en) 2020-11-05
IL287670A (en) 2021-12-01
JP2022537877A (en) 2022-08-31
MX2021013317A (en) 2022-01-18
WO2020222773A1 (en) 2020-11-05
AU2020266143A1 (en) 2021-12-02
BR112021021809A2 (en) 2022-01-04
CN119454692A (en) 2025-02-18
BR112021021826A8 (en) 2022-06-21
BR112021021826A2 (en) 2022-01-04
KR20220002489A (en) 2022-01-06
WO2020223431A1 (en) 2020-11-05
JP7453251B2 (en) 2024-03-19
CN114269336A (en) 2022-04-01
SG11202112018YA (en) 2021-11-29
CO2021015622A2 (en) 2022-02-28
EP3962476A1 (en) 2022-03-09
CO2021015614A2 (en) 2021-12-10
AU2019443366A1 (en) 2021-12-02
MA55799A (en) 2022-03-09
JP2022537878A (en) 2022-08-31
CN114206333A (en) 2022-03-18
EP3962475A1 (en) 2022-03-09
MX2021013318A (en) 2022-01-31
CA3138473A1 (en) 2020-11-05
SG11202112043PA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
CO2021015614A2 (en) Combination therapies comprising apremilast and tyk2 inhibitors
BR112021017495A2 (en) Pyrazine derivative and its application in shp2 inhibition
CL2021000382A1 (en) Novel sulfonamidaurea compounds
CL2020002146A1 (en) N- (phenyl) -2- (phenyl) pyrimidine-4-carboxamide derivatives and related compounds as hpki inhibitors to treat cancer.
MX2018005600A (en) Pharmaceutical compositions and methods for indoleamine 2,3-dioxygenase inhibition and indications therefor.
PH12022551475A1 (en) Fluoroalkyl-oxadiazoles and uses thereof
BR112015010477A2 (en) A pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases.
CR20220280A (en) COMBINATION THERAPY COMPRISING AN ALK2 INHIBITOR AND A JAK2 INHIBITOR
BR112015026021A2 (en) combination therapy comprising a tor kinase inhibitor and n- (3- (5-fluoro-2- (4- (2-methoxyethoxy) phenylamino) pyrimidin-4-ylamino) phenyl) acrylamide for cancer treatment
BR112023000687A2 (en) METHODS AND COMBINATIONS OF KAT6 INHIBITORS FOR THE TREATMENT OF CANCER
BR112023015210A2 (en) CDK2 INHIBITORS AND METHODS OF USE THEREOF
PH12021551282A1 (en) Radioimmunoconjugates and checkpoint inhibitor combination therapy
EA201691555A1 (en) METHODS OF TREATMENT AND PREVENTION OF KIDNEY DISEASES AND LIVER FATIAL DYSTROPHIES
EA201790907A1 (en) NEW PYRAZOLOPYRIMIDINE DERIVATIVES AS NIK INHIBITORS
EA202191955A1 (en) MODIFIED RELEASE TABLET FORMULATIONS CONTAINING PHOSPHODIESTERASE INHIBITORS
BR112022011892A2 (en) INTRANASAL PHARMACEUTICAL COMPOSITIONS OF CGRP INHIBITORS
WO2018208793A8 (en) S-nitrosoglutathione (gsno) and gsno reductase inhibitors for use in therapy
BR112022001270A2 (en) inhibitor compounds
MX2018008903A (en) COMPOSITIONS AND METHODS OF USE OF ß-HYDROXY-ß-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY.
CL2022001006A1 (en) tim-3 inhibitors and their uses
AR116024A1 (en) METHODS OF TREATMENT OF NEURODEGENERATIVE DISEASES
BR112022008580A2 (en) METHODS TO TREAT DEPRESSIVE DISORDERS
EA201990508A1 (en) ACTIVITY INHIBITION Olig2
CL2021002846A1 (en) Combination therapies comprising apremilast and tyk2 inhibitors
CL2021000282A1 (en) Ckd8 / 19 inhibitors